[PDF][PDF] Pharmacokinetics of ß-d-N4-hydroxycytidine, the parent nucleoside of prodrug molnupiravir, in non-plasma compartments of patients with SARS-CoV-2 …
S Khoo - 2022 - scienceopen.com
ABSTRACT ß-d-N4-hydroxycytidine (NHC), the parent nucleoside of molnupiravir, a COVID-
19 antiviral, was quantified at sites of SARS-CoV-2 transmission in twelve patients enrolled …
19 antiviral, was quantified at sites of SARS-CoV-2 transmission in twelve patients enrolled …
[PDF][PDF] Pharmacokinetics of ß-d-N4-hydroxycytidine, the active metabolite of prodrug molnupiravir, in non-plasma compartments of patients with SARS-CoV-2 infection.
GG Ewings, S Khoo - scholar.archive.org
Background: Molnupiravir, an orally administered prodrug of the broadly active, direct-acting
antiviral, ribonucleoside analogue ß-d-N4-hydroxycytidine (NHC) is a promising COVID-19 …
antiviral, ribonucleoside analogue ß-d-N4-hydroxycytidine (NHC) is a promising COVID-19 …
[PDF][PDF] S3-Leitlinie-Empfehlungen zur stationären Therapie von Patienten mit COVID-19
F Fichtner, S Laudi, M Stegemann, S Weibel - virtuelles-krankenhaus.nrw
Seit Dezember 2019 verbreitet sich das neuartige Coronavirus SARS-CoV-2 (Severe Acute
Respiratory Syndrome–Corona Virus-2) rasch im Sinne einer weltweiten Pandemie. Dies …
Respiratory Syndrome–Corona Virus-2) rasch im Sinne einer weltweiten Pandemie. Dies …
[PDF][PDF] ACTUALIZACIONES BASADAS EN EVIDENCIA COVID-19
DESC DE TECNOLOGÍAS - argentina.gob.ar
El remdesivir fue evaluado originalmente en ensayos clínicos para abordar el brote de virus
del ébola en 2014.(13) Con la demostración de que remdesivir poseía una amplia actividad …
del ébola en 2014.(13) Con la demostración de que remdesivir poseía una amplia actividad …
[HTML][HTML] Molnupiravir–Updated Recommendation
ES Team, H Alexander - indiacovidguidelines.org
Background Molnupiravir was the first oral antiviral treatment developed specifically for
COVID-19 developed by Merck, Sharp and Dohme and Ridgeback Therapeutics …
COVID-19 developed by Merck, Sharp and Dohme and Ridgeback Therapeutics …
[PDF][PDF] Clinical Trials Registration. NCT04746183.
R FitzGerald, L Dickinson, L Else, T Fletcher, C Hale… - 2022 - pdfs.semanticscholar.org
Molnupiravir pharmacokinetics were evaluated as part of a phase 1 dose-escalation study
(300, 600, and 800 mg twice daily) in patients with polymerase chain reaction–confirmed …
(300, 600, and 800 mg twice daily) in patients with polymerase chain reaction–confirmed …
[HTML][HTML] Can Molnupiravir Prevent or Treat COVID-19 Infection?
B Age, B Season, DC Metro, CBB Ingestions, A Fast… - poison.org
Molnupiravir is an oral medication currently being investigated as a treatment for COVID-19
infection and has been shown to be safe and effective in clinical trials. The pharmaceutical …
infection and has been shown to be safe and effective in clinical trials. The pharmaceutical …
[引用][C] Комп'ютерне моделювання взаємодії тілорону та молнупіравіру з модельними мембранами та рецептор-зв'язуючим доменом спайк-білка SARS-CoV-2
Є Брюховецька - 2022
[引用][C] Thuốc kháng virus cấu trúc phân tử nhỏ trong điều trị COVID-19: Qúa trình khám phá, cơ chế tác động và thử nghiệm lâm sàng
MT Tấn, LT Phong, ĐNB Trân, LVT Nghĩa, TK Minh… - Health Sciences, 2022